Pentosan Polysulfate Sodium and Maculopathy in Patients with Interstitial Cystitis: A Systematic Review and Meta-Analysis

被引:0
|
作者
Lee, Jongsoo [1 ]
Kim, Yun Jin [2 ]
Lee, Konghee [3 ]
Kim, Young Kook [4 ,5 ]
Rhee, Taeho Greg [6 ,7 ]
Shim, Sung Ryul [8 ,9 ,10 ]
Kim, Jae Heon [11 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Urol, Seoul, South Korea
[2] Soonchunhyang Univ, Bucheon Hosp, Dept Pathol, Bucheon 14584, South Korea
[3] Zenit Urol Clin, Chang Won, South Korea
[4] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea
[5] EyeLight Data Sci Lab, Seoul, South Korea
[6] Yale Sch Med, Dept Psychiat, New Haven, CT USA
[7] Univ Connecticut, Sch Med, Dept Publ Hlth Sci, Farmington, CT USA
[8] Konyang Univ, Coll Med, Dept Biomed Informat, 158 Gwanjeodong Ro, Daejeon 35365, South Korea
[9] Konyang Univ Hosp, Konyang Med Data Res Grp KYMERA, Daejeon 35365, South Korea
[10] Konyang Univ Hosp, Myunggok Med Res Ctr, Daejeon, South Korea
[11] Soonchunhyang Univ, Coll Med, Dept Urol, Seoul Hosp, 59 Daesagwan Ro, Seoul 04401, South Korea
来源
WORLD JOURNAL OF MENS HEALTH | 2025年
关键词
Cystitis; interstitial; Drug-related side effects and adverse reactions; Macular degeneration; Pentosan sulfuric polyes- ter; Retinal diseases; PREVALENCE; SYMPTOMS;
D O I
10.5534/wjmh.240295
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Purpose: Pentosan polysulfate sodium (PPS) is the only pharmacological intervention approved by the US Food and Drug Administration for treating interstitial cystitis (IC) to date. However, PPS may induce an adverse event, maculopathy, which can be a significant challenge. To determine the risk of PPS-induced maculopathy in patients with IC. Materials and Methods: PubMed and Embase were systematically searched through July 2024. Two authors also independently and manually searched all relevant studies. We included national level cohort studies using healthcare claim big data or real-world data with the following criteria: (1) patients diagnosed with IC; (2) interventions included PPS as an active treatment; (3) comparisons were specified as non-PPS interventions; and (4) the primary outcome of interest was the risk of maculopathy. The pairwise meta-analysis was performed to compare the PPS treatment group with control used in IC. The primary outcome measure was the hazard ratio (HR), odds ratio (OR), and proportional report ratio (PRR) of maculopathy after receiving the PPS treatment, as compared to non-PPS interventions. Results: A comprehensive literature search was conducted, and identified 6 studies with 411,098 patients. The pooled risk for maculopathy due to PPS in patients with IC was significant (HR, 1.678; 95% confidence interval [95% CI], 1.066-2.642]). The heterogeneity test produced a Higgins' I-squared statistic, which was 83.6%. In the subgroup analysis of follow-up period of less than 5 years (HR, 1.285; 95% CI, 1.139-1.449) and more (HR, 1.341; 95% CI, 1.307-1.375) were statistically significant, indicating that the patients with IC who had a long-term PPS treatment were more likely to have maculopathy than the control groups. Conclusions: This is the first study to investigate the relationship between PPS and its association with the risk of maculopathy in patients with IC through a systematic review and meta-analysis.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Risk of maculopathy with pentosan polysulfate sodium use
    Bae, Steven S.
    Sodhi, Mohit
    Maberley, David
    Kezouh, Abbas
    Etminan, Mahyar
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (07) : 3428 - 3433
  • [12] Visual Function in Pentosan Polysulfate Sodium Maculopathy
    Lyons, Riley J.
    Brower, Judy
    Jain, Nieraj
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (13)
  • [13] Prevalence and Dose Dependency Analysis of Pentosan Polysulfate Sodium Maculopathy
    Philip, Andrew M.
    Wannamaker, Kendall W.
    Miller, Daniel M.
    OPHTHALMIC EPIDEMIOLOGY, 2023, 30 (01) : 82 - 87
  • [14] Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: A randomized comparative study
    Sairanen, J
    Tammela, TLJ
    Leppilahti, M
    Multanen, M
    Paananen, I
    Lehtoranta, K
    Ruutu, M
    JOURNAL OF UROLOGY, 2005, 174 (06): : 2235 - 2238
  • [15] Pentosan Polysulfate-Associated Macular Disease in Patients With Interstitial Cystitis
    Lyons, Riley J.
    Ahmad, Samera
    Ansari, Sana
    Foote, Jenelle E.
    Jain, Nieraj
    OBSTETRICS AND GYNECOLOGY, 2020, 135 (05): : 1091 - 1094
  • [16] Pentosan Polysulfate-Associated Macular Disease in Patients With Interstitial Cystitis
    Lyons, Riley J.
    Ahmad, Samera
    Ansari, Sana
    Foote, Jenelle E.
    Jain, Nieraj
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2020, 75 (10) : 598 - 599
  • [17] Progression of Pentosan Polysulfate Sodium Maculopathy in a Prospective Cohort
    Somisetty, Swathi
    Santina, Ahmad
    Au, Adrian
    Romero-morales, Veronica
    Bousquet, Elodie
    Sarraf, David
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2023, 255 : 57 - 67
  • [18] PENTOSAN POLYSULFATE SODIUM (ELMIRON) MACULOPATHY A Genetic Perspective
    Kalaw, Fritz Gerald P.
    Ignacio, John Carlos I.
    Wu, Chris Y. Y.
    Ferreyra, Henry
    Nudleman, Eric
    Baxter, Sally L.
    Freeman, William R.
    Borooah, Shyamanga
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2023, 43 (07): : 1174 - 1181
  • [19] Progressive Maculopathy After Discontinuation of Pentosan Polysulfate Sodium
    Huckfeldt, Rachel M.
    Vavvas, Demetrios G.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2019, 50 (10): : 656 - 659
  • [20] Long-term use of pentosan polysulfate for interstitial cystitis
    Evans, RJ
    UROLOGY, 1999, 53 (04) : 863 - 863